Johnson & Johnson's nasal spray for depression wins FDA panel backing

An advisory panel to the U.S. Food and Drug Administration on Tuesday voted in favor of Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, bringing the drug closer to approval.